Granules India Ltd
NSE: GRANULES BSE: 532482
₹586.20
(0.84%)
Wed, 18 Mar 2026, 08:51 pm
Market Cap140.95B
PE Ratio26.07
Dividend0.26
Health Technology
Pharmaceuticals: Other
24.5KCompany History
1985
- M/s.Triton Laboratories (TL), a partnership firm was promoted by the promoters.
1991
- Granules India Ltd was incorporated as a Private Limited Company on March 16.
- GIL commenced its operations in April as a merchant exporter of bulk drugs like Paracetamol, Guaifenesin and Chloro Pheniramine Maleste.
1992
- GIL concentrated on the export of Paracetamol powder.
1993
- GIL was converted into a Public Limited Company on February 8.
- GIL joined as a partner of M/s.Triton Laboratories (TL), a partnership firm promoted by the promoters in 1985.
- TL decided to diversify into manufacturing of bulk drugs and started implementing a project for the same.
- The value of land purchased in 1985 was revalued at Rs.28,26,980 on March 30.
1994
- Trial production of Folic Acid commenced in November.
- GIL started implementing the ongoing project taken over from TL and exported DC blends of Paracetamol of international pharmacopial standards from September 1.
- GIL purchased the assets of a sick unit from the Andhra Pradesh State Financial Corporation (APSFC) on March 30.
1995
- Commercial production of Folic Acid commenced in August.
2003
- Granules MD Mr C. Krishna Prasad bagged the Udyog Rattan and Excellence Award.
2004
- Granules India Ltd announced that its new plant at Gagillapur had successfully gone through the first International Regulatory audit by the German Health Authority.
- Granules India Gagillapur Facility successfully went through an audit by the German Health Authority.
2005
- Granules India Ltd informed that the GDR issue was opened on January 13, 2005 and closed on January 19, 2005.
2006
- Granules India Ltd signed a Memorandum of Understanding (MoU) with Hubei Biocause Heilen Pharmaceutical Company (Biocause) of China.
- Granules India signed MOU with PharmaMatch B.V.
2007
- Granules forges alliance with GSK Healthcare R&D.
- Mr. Stephen R Olsen was appointed as an Additional Director of the Company.
- The Registered Office of the Company was shifted from 8-2-293/A/A/2, Road No 2, Banjara Hills, Hyderabad to Second Floor, Block III, My Home Hub, Madhapur, Cyberabad.
2008
- Mr. Nelson David Corda was appointed as Alternate Director.
2009
- Mr. Comandur Parthasarathy was appointed as an Additional Director of the Company.
- Granules India Limited bagged the prestigious 'Fastest Emerging Company from India' Award in the APIs & Intermediaries category.
2010
- Mr. Philip Herbert Strenger was appointed as an Additional Director of the Company.
- Granules India received U.S. FDA approval for its Metformin ANDA.
- Granules India announced new leadership roles.
2011
- Ms. Shivangi Sharma was appointed as Company Secretary and Compliance Officer of the Company.
- Granules-Omnichem Ltd planned to open a unit in Vizag.
- Granules India and Ajinomoto OmniChem created a strategic Joint Venture in India.
2012
- Granules India was awarded India's Most Admired Company in Exports and India's Most Admired Company in Bulk Drugs.
- Granules India was awarded Outstanding Exports - Formulations Award 2011-12 by Pharmexcil.
2013
- Granules India announced acquisition of Auctus Pharma and opening of a new R&D Facility.
- Granules completed a major expansion at its Gagillapur facility.
- Granules India recommended a Final dividend of Rs. 2.00 per share representing 20% of Paid Up Capital.
2014
- Granules India's Paracetamol API Facility completed U.S. FDA Inspection.
- Granules India was awarded Outstanding Exports (Europe & CIS) - Gold Award 2012-13 by Pharmexcil.
- Granules India recommended a final dividend of Rs. 3.50 per share representing 35% of Paid Up Capital.
2015
- Granules India received US FDA approval for Ibuprofen Tablets.
- Granules India's two facilities located in Vizag and Jeedimetla completed U.S FDA inspection.
- Granules India split its face value from Rs. 10 to Rs. 1.
2016
- Granules acquired rights for 4 products from USpharma Windlas.
- Granules Pharmaceuticals, Inc., a wholly owned subsidiary of Granules India Ltd, entered into an agreement with USpharma to acquire its stake.
2017
- Granules India successfully completed INFARMED re-inspection.
- Granules India got Board nod to raise FII, FPI limit to 49%.
- Granules India got EIR from USFDA for Vizag OmniChem facility.
2018
- Granules Pharmaceuticals, Inc. launched the generic version of Methylergonovine Maleate Tablets, USP, 0.2mg.
- Granules Pharmaceuticals, Inc. received US FDA approval for generic Methylergonovine tablets.
- Granules India got USFDA nod for muscle pain tablets.
- Granules India received approval for ANDA filed by Granules India Limited.
- Granules' US unit got two USFDA observations.
2019
- Granules India got USFDA nod for pain relief drug.
- Granules India got USFDA nod for treatment of attention deficit hyperactivity disorder.
- Granules India received US FDA approval for Methylphenidate Hydro.
- Granules India's Bonthapally Facility completed US FDA inspection.
- Granules India got USFDA nod for Amphetamine Sulfate tablets.
- Granules Pharmaceuticals, Inc. received US FDA approval for Amphetamine Sulfate Tablets.
2020
- Granules India arm got USFDA nod for Valganciclovir hydrochloride oral solution.
- Granules India received USFDA approval for Colchicine Tablets.
- Granules Pharmaceuticals Inc. got USFDA nod for Colchicine tablets.
- Granules India got tentative USFDA nod for Colchicine capsules for gout.
- Granules India got tentative nod from USFDA for expectorant tablets.
2021
- Granules got USFDA nod for diabetes management drug.
- Granules India got USFDA nod for generic low blood potassium treatment capsules.
- Granules India received USFDA approval for Acetaminophen, Aspirin and Caffeine Tablets.
- Granules India received USFDA approval for Dofetilide capsules.
- Granules India's US unit got two observations from USFDA.
2022
- Granules India received licenses from MPP to market Nirmatrelvir and Ritonavir.
- Granules Pharmaceuticals Inc. received ANDA approval for Bupropion Hydrochloride Extended-Release Tablets.
- Granules Pharmaceuticals Inc. received ANDA approval for Potassium Chloride for Oral Solution USP, 20 mEq.
2023
- Granules India received USFDA approval for Losartan Potassium Tablets.
- Granules India forged a strategic partnership with Greenko ZeroC.
2024
- Granules India Limited was honored with the Golden Peacock Award for Sustainability.
- Granules India received approval from the US health regulator to market a generic medication to treat major depressive disorder.
- The company received approval from the US Food & Drug Administration for Bupropion Hydrochloride extended-release tablets USP (SR) in strength of 100 mg, 150 mg, and 200 mg.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800